SG11201802091RA - Fungal keratitis prophylactic or therapeutic agent - Google Patents

Fungal keratitis prophylactic or therapeutic agent

Info

Publication number
SG11201802091RA
SG11201802091RA SG11201802091RA SG11201802091RA SG11201802091RA SG 11201802091R A SG11201802091R A SG 11201802091RA SG 11201802091R A SG11201802091R A SG 11201802091RA SG 11201802091R A SG11201802091R A SG 11201802091RA SG 11201802091R A SG11201802091R A SG 11201802091RA
Authority
SG
Singapore
Prior art keywords
prophylactic
therapeutic agent
fungal keratitis
keratitis
fungal
Prior art date
Application number
SG11201802091RA
Other languages
English (en)
Inventor
Jinzhong Zhang
Masaaki Kageyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201802091RA publication Critical patent/SG11201802091RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201802091RA 2015-09-18 2016-09-13 Fungal keratitis prophylactic or therapeutic agent SG11201802091RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (1)

Publication Number Publication Date
SG11201802091RA true SG11201802091RA (en) 2018-04-27

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201802091RA SG11201802091RA (en) 2015-09-18 2016-09-13 Fungal keratitis prophylactic or therapeutic agent

Country Status (13)

Country Link
US (1) US10166217B2 (cg-RX-API-DMAC7.html)
EP (1) EP3351244A4 (cg-RX-API-DMAC7.html)
JP (1) JP6639364B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180053340A (cg-RX-API-DMAC7.html)
CN (1) CN108025000A (cg-RX-API-DMAC7.html)
BR (1) BR112018005305A2 (cg-RX-API-DMAC7.html)
HK (2) HK1256969A1 (cg-RX-API-DMAC7.html)
MX (1) MX393608B (cg-RX-API-DMAC7.html)
MY (1) MY183906A (cg-RX-API-DMAC7.html)
PH (1) PH12018500579A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201802091RA (cg-RX-API-DMAC7.html)
TW (1) TWI721015B (cg-RX-API-DMAC7.html)
WO (1) WO2017047597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2187743B1 (en) * 2007-08-16 2014-07-30 Santen Pharmaceutical Co., Ltd Rapamycin formulations for treatment of age related macular degeneration

Also Published As

Publication number Publication date
BR112018005305A2 (pt) 2018-10-09
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
JP2017057199A (ja) 2017-03-23
KR20180053340A (ko) 2018-05-21
MY183906A (en) 2021-03-17
WO2017047597A1 (ja) 2017-03-23
MX393608B (es) 2025-03-24
EP3351244A4 (en) 2019-05-01
TWI721015B (zh) 2021-03-11
CN108025000A (zh) 2018-05-11
US20180271841A1 (en) 2018-09-27
PH12018500579A1 (en) 2018-09-10
MX2018003381A (es) 2018-08-15
HK1256969A1 (en) 2019-10-04
US10166217B2 (en) 2019-01-01
TW201717943A (zh) 2017-06-01
JP6639364B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
IL255270A0 (en) exoskeleton
GB201607550D0 (en) Ride-sharing range contours
GB201513540D0 (en) Therapeutic agents
GB201509919D0 (en) Coating
GB201509893D0 (en) Therapeutic agents
HUE045330T2 (hu) Légnyomó szivattyú
GB201517263D0 (en) Therapeutic agents
AU201813556S (en) Fender
ZA201801891B (en) Blasting agent
PL3285606T3 (pl) Ochrona ciała
PL3481933T3 (pl) Środek zapobiegający szarzeniu
GB201514938D0 (en) Braring calculation
GB201509885D0 (en) Therapeutic agents
GB2546811B (en) Frustum rendering
IL256195A (en) Coating
GB201509888D0 (en) Therapeutic agents
GB201601431D0 (en) Pyrrolobenzodiazepines
GB201513299D0 (en) Therapeutic agents
GB2547792B (en) Retractors
SI3168768T1 (sl) Zaščita programske opreme
GB201714777D0 (en) Agent
EP3351244A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR PURPOSE CERATITIS
GB201620641D0 (en) Agent
GB201517264D0 (en) Therapeutic agents
GB2546366B (en) Software protection